BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cipla
Fuji
Novartis
Teva
Dow
Moodys
Medtronic
Fish and Richardson
Deloitte

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,956,651

« Back to Dashboard

Which drugs does patent 8,956,651 protect, and when does it expire?

Patent 8,956,651 protects RELISTOR and is included in one NDA.

This patent has forty patent family members in twenty-nine countries.
Summary for Patent: 8,956,651
Title:Oral formulations and lipophilic salts of methylnal trexone
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Inventor(s): Shah; Syed M. (Delray Beach, FL), Diorio; Christopher Richard (Campbell Hall, NY), Ehrnsperger; Eric C. (New City, NY), Meng; Xu (San Diego, CA), Al Shareffi; Kadum A. (North Potomac, MD), Cohen; Jonathan Marc (Monroe, NY)
Assignee: Wyeth, LLC (Madison, NJ)
Application Number:13/966,779
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Device;

Drugs Protected by US Patent 8,956,651

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,956,651

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,524,276 Oral formulations and lipophilic salts of methylnaltrexone ➤ Subscribe
9,314,461 Oral formulations and lipophilic salts of methylnaltrexone ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,956,651

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland 2371357 ➤ Subscribe
Peru 00632013 ➤ Subscribe
New Zealand 703564 ➤ Subscribe
New Zealand 702826 ➤ Subscribe
New Zealand 601595 ➤ Subscribe
Malaysia 160727 ➤ Subscribe
Mexico 349145 ➤ Subscribe
Mexico 2012009125 ➤ Subscribe
Morocco 34146 ➤ Subscribe
South Korea 20130010900 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Novartis
Teva
Chubb
Farmers Insurance
McKesson
Citi
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot